Increase of Suicide and Accidental Death After Hematopoietic Stem Cell Transplantation

A Cohort Study on Behalf of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

BACKGROUND: Relapse and transplant-related complications are leading causes of mortality after hematopoietic stem cell transplantation (HSCT). Suicides and accidents have not been studied in these patients. This study sought to determine whether there is an excess of suicide and accidental deaths after HSCT, and to determine risk factors. METHODS: The incidence of suicidal and accidental death in patients after undergoing HSCT, standardized mortality ratio (SMR), and absolute excess risk (AER) of suicide and accidental deaths was determined, compared with the general European population. A case-control analysis was done to define factors associated with suicide and accidental deaths. Data were derived from the European Group for Blood and Marrow Transplantation Registry, including 294,922 patients who underwent autologous or allogeneic HSCT from 1980 to 2009. RESULTS: The 10-year cumulative incidence of suicide and accidental deaths was 101.8 and 55.6 per 100,000 patients, respectively. SMR and AER of suicide after HSCT were 2.12 ($P < .001$) and 10.91, higher than in the European general population for 100,000 deaths, respectively. SMR and AER of accidental death were 1.23 ($P < .05$) and 2.54, respectively. In the case-control study, relapses were more frequent among patients who committed suicide after autologous HSCT (37% versus 18%; $P < .0001$). Chronic graft-versus-host disease was higher among patients who committed suicide after allogeneic HSCT (64% versus 37%; $P = .001$). CONCLUSIONS: There is an excess of deaths due to suicide and accidents in patients after undergoing HSCT as compared with the European general population. Relapse was associated with more suicide and accidental deaths after autologous HSCT, and chronic graft-versus-host disease was associated with more deaths by suicide after allogeneic HSCT. Cancer 2013;119:2012-21. © 2013 American Cancer Society.

INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) is a treatment option for a variety of malignant and nonmalignant disorders.1-3 Overall survival has improved substantially over the last decade,4 but HSCT remains associated with considerable early and late treatment-related morbidity and mortality. When compared to a matched general population, mortality remains increased.5-7 Relapse of the primary disease and transplant-related mortality are the main causes of mortality after HSCT. With longer follow-up, other causes of death are observed, such as deaths from secondary malignancies, cardiovascular diseases, and other late organ dysfunctions.8,9 External causes of death, such as suicide and accident, are usually considered to be unrelated to the HSCT.

Suicide and accident are an important cause of death in a general population worldwide. In population-based epidemiological studies, cancer survivors have an elevated risk for committing suicide.10,11 Regarding accident-related deaths, there are no data for cancer patients. However, physical and psychological disabilities due to cancer and/or its treatment could intuitively lead to an excess of death from accidents. In patients treated with HSCT, the risk of suicide and accidents has never been systematically evaluated. Compared with patients who received recent cancer diagnoses, the situation is quite different, because patients who undergo HSCT have in most cases already been confronted with the diagnosis of malignancy, and have undergone intensive chemotherapy.

DOI: 10.1002/cncr.27987, Received: September 23, 2012; Revised: November 7, 2012; Accepted: November 14, 2012, Published online March 19, 2013 in Wiley Online Library (wileyonlinelibrary.com)
Rates. It is therefore reasonable to assume that physical
with reduced driving performance and increased crash
use of some medications, drugs, and alcohol are linked
to adequately solve activities of daily living (causing for
instance impaired driving capacity), and therefore be re-
 sponsible for an excess of accidents after HSCT.

For these reasons, we expected an excess of deaths
due to suicide and accidents in patients who were treated
with HSCT. We therefore sought to estimate in a large
cohort of patients from the European Group for Blood
and Marrow Transplantation (EBMT) registry the risk of,
and factors associated with, death from suicide and acci-
dents among patients treated with HSCT, compared with
the death rates of the European population in general.

MATERIALS AND METHODS

Database Population

This retrospective observational study was based on the
mandatory minimum data set centers reported to the
EBMT. The EBMT maintains a patient database
known as the EBMT registry that goes back to the be-
inning of the 1970s and contains patient clinical data,
including aspects of the diagnosis, first-line treatment,
HSCT-associated procedures, complications, and out-
come. Patients are reported exhaustively and followed
up indefinitely; data are collected prospectively. Accord-
ing to the guidelines of the EBMT registry, it is the
center’s responsibility to ensure that the patient has pro-
vided consent before data is forwarded to the EBMT.
As of March 2011, the EBMT database included
380,227 patients, from 661 transplant centers in 53
countries, who underwent autologous or allogeneic
HSCT. We restricted the analysis to patients treated for
hematological malignancy, solid tumors, marrow failure
syndrome, and autoimmune diseases, who underwent
transplantation between 1980 and 2009, excluding
those with missing data on survival state, type of trans-
plantation (autologous versus allogeneic), initial diago-
nosis, as well as patients who underwent transplantation
for inborn errors. For patients who underwent trans-
plantation more than once, only first the transplant was
considered. Finally, 294,922 patients (77.6%) reported
to the EBMT were included in this analysis. Causes of
death were reported by transplant centers to the EBMT
registry. We based the study on this source of data.

Cohort Analysis

The primary endpoints were the cumulative incidence of
death from suicide and accident, the deaths rates by sui-
cide and accident, as well as the standardized mortality ra-
tio (SMR) and the absolute excess risk (AER) of suicides
and accidents compared with the general European
population. Cause of death was defined as nonexternal
(relapse-related deaths, transplant-related mortality, late
transplant-related deaths such as late organ failure, sec-
dary tumors) and external causes of deaths, which were
defined as a death due to accident or suicide, according to
the International Statistical Classification of Diseases and
Related Health Problems, 10th Revision (ICD-10) from the
World Health Organization. For this study, deaths by
euthanasia or murder were not included in the group of
external deaths. The cumulative incidence of death by
suicide and accident after HSCT was calculated taking
into consideration the competing risk of death due other
causes. The time to risk was computed from the date of
HSCT to the date of death or the date of last contact. Uni-
ivariate analyses were performed using the Gray test. Fac-
tors considered were patient-related (sex, age), disease-
related (diagnosis, disease status at HSCT), and type of
transplant (autologous or allogeneic). Multivariate analysis was performed to calculate hazard ratio (HR) and their 95% confidence intervals (CI), adjusted for all covariates, using Cox proportional hazards regression model.

The statistics from the Eurostat, the statistical office of the European Union, which provides information at the European level including data from 15 representative European countries, were used to generate sex-specific death rates for suicide and accidents. These death rates were used to calculate expected number of cases for our cohort. The SMR was calculated by obtaining the ratio of the observed and expected number of cases. The 95% CIs were estimated using a method described by Haenszel. The AER of death by suicide and accident per 100,000 person-years of observation was calculated by subtracting the number of expected deaths from the observed, dividing by person-years of follow-up for the HSCT cohort multiplied by 100,000.

**Case-Control Analysis**

We used a nested case-control approach to identify prognostic factors related to disease and HSCT characteristics on risk of death by suicide and accidents after HSCT. For each case of suicide and accident, 3 controls were selected within the cohort according to the following matching criteria: type of HSCT, age at HSCT by decade, patient sex, year of transplantation, and length of follow-up (control’s follow-up was equivalent to, or exceeded that, of the index case). Prognostic factor analyses were performed separately for allogeneic and autologous HSCT. Cases and controls were compared with respect to disease, disease stage at HSCT (standard versus high risk), type of donor, and relapse (for controls, relapse occurring at equivalent time to or before death of the index case). For the allogeneic HSCT cohort, cases and controls were further compared with respect to type of conditioning (myeloablative versus reduced intensity), total body irradiation TBI for patients treated with myeloablative conditioning, and GVHD (for controls, GVHD occurring at equivalent time to or before death of the index case). A conditional logistic regression was used to compare the 2 groups and to estimate ORs. All P values are 2-sided with type I error rate fixed at .05. Statistical analyses were performed with SPSS Statistic 19 (IBM Corporation) and R 2.13.2 software packages (R Development Core Team, Vienna, Austria).

**RESULTS**

**Cohort Analysis**

From the 294,922 patients included in the cohort study, 108,951 patients (36.9%) had received allogeneic and 185,971 patients (63.1%) had received autologous HSCT. From this cohort, 57% were males. The median age at HSCT was 34.2 years at allogeneic and 48.4 years at autologous HSCT. Most patients (96%) underwent transplantation for hematological malignancies; 53% were considered as standard and 47% high-risk at time of HSCT. More than 60% of the patients underwent transplantation after 2000; the median follow-up of patients alive at last follow-up was 2.34 years (range, 1 day to 31 years).

**Causes of Death After HSCT**

In total, 116,149 patients (39.4%) died. The main causes of death were relapse in 61,605 patients (57.5%), transplant-related mortality in 38,600 patients (36%), and late transplant-related causes of death in 6671 patients (6.5%). There were 314 (0.27%) external causes of death, 189 suicides, and 125 deaths by accident.

Of the 189 patients with death from suicide, 140 (74%) were males, 74 (39%) received allogeneic HSCT, and 115 (61%) received autologous HSCT. The median age at HSCT and at suicide was 45 years (range, 6-73 years) and 46 years (range, 16-73 years), respectively. The median time interval between HSCT and suicide was 13 months (range, 1-292 months). Death due to suicide after HSCT occurred within the first year in 86 patients (46%), and during the second year in 29 patients (15%). In 32 patients (17%), suicide occurred after 5 years (Fig. 1A).

Of the 125 patients with death from accident, 92 (74%) were males, 48 (38%) received allogeneic HSCT, and 77 (62%) received autologous HSCT. The median age at HSCT and at time of the accidental death was 41 years (range, 1-69 years) and 45 years (range, 2-71 years), respectively. The median time interval between HSCT and accident was 13 months (range, 1-292 months). Death due to accident occurred within the first year in 40 patients (32%) and during the second year in 22 patients (18%). In 30 patients (24%), accidents occurred after 5 years (Fig. 1B). Fifty-one patients died of traffic accident, 9 of fall, 6 of drowning, 2 of farm accident, and 2 of fire. In 55 cases (44%), the type of accident was not further specified.

**Cumulative Incidence and Risk Factors**

The cumulative incidence of suicide death at 5 and 10 years was 72.9 and 101.8 per 100,000 patients, respectively. It was 72 and 100 per 100,000 patients for allogeneic HSCT, and 73 and 101 per 100,000 patients for autologous HSCT (P=.71), respectively (Fig. 2A).
The cumulative incidence of accidental death at 5 and 10 years after HSCT was 47.4 and 55.6 per 100,000 patients, respectively. It was 44 and 70 per 100,000 patients for allogeneic HSCT, and 49 and 66 per 100,000 for autologous HSCT \( (P = .47) \) (Fig. 2B).

Results of univariate analysis are summarized in Table 1. By multivariate analysis, suicide rate after HSCT was lower in females compared with males (OR = 0.43, 95% CI = 0.30-0.61; \( P = .0001 \)), and significantly associated with age \( (P = .001) \) (Table 2). After HSCT, accidental deaths were less frequent in females (OR = 0.45; 95% CI = 0.30-0.68; \( P = .0001 \)) (Table 2).

**Suicide Death Rates**

The suicide death rate was 20.7 per 100,000 person-years after HSCT. The suicide death rates were 27.4 and 14.0 per 100,000 person-years for males and females, respectively. The total expected suicide death rates according to Eurostat are 9.2 per 100,000 person-years (males, 14.0; females, 4.4) (Table 3). Thus, the SMR and the AER after HSCT were 2.12 (95% CI = 1.83-2.45; \( P < .001 \)), and 10.91 higher than in the European for 100,000 deaths, respectively. Standardized rates were higher both in males (SMR, 1.96; 95% CI = 1.65-2.31; \( P < .001 \); AER, 13.4) and in females (SMR, 2.77; 95% CI = 2.05-3.67; \( P = .001 \); AER, 7.81) (Table 3).

We further compared the suicide death rates among age groups at time of HSCT (Fig. 3A). As in the general population, there was a continuous increase in the death rates in the whole cohort, as well as in males and in females when they were analyzed separately. In the whole cohort, it increased from 5.0 deaths per 100,000 person-years for patients aged 1 to 14 years at time of HSCT up to 34 deaths per 100,000 person-years in patients older than 65 years.
Accidental Death Rates

Accidental death rates after HSCT were 13.7 per 100,000 person-years (males, 18.0; females, 8.2). The expected accident death rates in the European general population, according to Eurostat statistics, are 10.5 per 100,000 person-years (males, 16.3; females, 4.9). Thus, the SMR and AER were 1.23 (95% CI = 1.02-1.46; \( P = .05 \)) and 2.54, respectively. Standardized death from accident was significantly increased in females (SMR, 1.83; 95% CI = 1.26-2.57; \( P = .01 \)) but not in males (SMR, 1.11; 95% CI = 0.89-1.36) (Table 3). We also compared accident death rates by age groups at the time of HSCT (Fig. 3B). These death rates were lowest in patients who underwent transplantation before the age of 15 years (7.6 deaths) and highest in patients older than 55 years at time of HSCT (18.7 deaths). For patients aged between 15 and 55 years at the time of HSCT, however, there was a constant death rate between 12 and 15 accident deaths per 100,000 person-years.

Case-Control Study

The 189 patients with suicide (cases) were matched with 560 patients who did not die from suicide (controls). Pre-transplant factors, relapse rate, GVHD incidence, type of conditioning, and donor type are summarized for cases and controls in Table 4. Relapses were significantly more frequent among patients who died from suicide (52 of 189 patients [28%] versus 81 of 560 patients [15%]; \( P = .02 \)). This difference was observed in patients who underwent autologous HSCT (37% [42 of 115 patients] versus 18% [60 of 342 patients]; \( P < .0001 \)), but not in those treated with allogeneic HSCT (14% [10 of 71 patients] versus 10% [21 of 212 patients]; \( P = .33 \)). The prevalence of chronic GVHD was significantly higher among patients who committed suicides after allogeneic HSCT and who survived at least 100 days, as compared with controls (64% [29 of 45 patients] versus 37% [62 of 168 patients]; \( P = .001 \)).

The 125 patients with accidents (cases) were matched with 372 patients who did not die from accidents (controls). Relapse in patients treated with autologous HSCT was significantly more frequent in patients who died from accidents than in controls (28% [21 of 76 patients] versus 14% [33 of 228 patients]; \( P = .009 \)). This was not the case for patients treated with allogeneic HSCT.

Conditional logistic regression analysis was performed in patients treated with allogeneic and autologous HSCT. Patients who experienced chronic GVHD after allogeneic HSCT had a 2.9-fold (OR = 2.91; 95% CI = 1.16-7.23; \( P = .002 \)) and patients relapsing after autologous HSCT had a 4.5-fold (OR = 4.48; 95% CI = 2.3-8.76; \( P < .0001 \)) increased risk of dying from suicide (Table 5).

DISCUSSION

This study, which included a large cohort of European patients, demonstrates for the first time that there is an excess of deaths due to suicide and accident after HSCT as compared with the European general population. The suicide death rate of the patients who underwent transplantation exceeded that of the European general population by a factor of 2, and there is a 10-fold increase of the absolute excess risk. SMR and AER were also increased for death from accident, a difference mainly observed in female patients.
patients. The overall risk factors for death related to suicide were male sex and older age. Despite similar cumulative incidences between autologous and allogeneic HSCT, factors linked to suicides and accidents appeared different; relapse was associated with more deaths by suicide and accident after autologous HSCT and chronic GVHD, with more deaths by suicide after allogeneic HSCT.

In the general population, risk groups for suicide include mainly male sex, older age, unemployment, drug abuse, mental illness, and depression. However, it now becomes evident that chronic physical illness is a relevant risk factor.25-27 One in 10 suicides is among people with a physical illness,28 and patients with cancer have nearly twice the expected incidence of suicide.10,11,29,30

### TABLE 2. Multivariate Analysis for Risk Factors for Suicidal and Accidental Deaths: Cohort Study

| Characteristic                          | Suicidal Deaths | Accidental Deaths |
|----------------------------------------|-----------------|-------------------|
|                                       | 95% CI          | 95% CI            |
|                                       | P   | HR inf | HR sup | P   | HR inf | HR sup |
| Autologous versus allogeneic           | .93  | 0.98   | 0.62   | 1.54 | .64    | 0.95   | 0.55   | 1.62 |
| Sex                                    |      |        |        |      |        |        |        |      |
| Male (reference)                       | 1    | 1      |        |      |        |        |        |      |
| Female                                 | <.0001| 0.43   | 0.30   | 0.61 | <.0001| 0.45   | 0.30   | 0.68 |
| Age at HSCT, y                         |      |        |        |      |        |        |        |      |
| 1-14 (reference)                       | .001 |        |        | .23  |        |        |        |      |
| 15-24                                  | .06  | 2.54   | 0.97   | 6.68 | .04    | 2.43   | 1.04   | 5.70 |
| 25-34                                  | .001 | 4.47   | 1.80   | 11.09| .009   | 3.07   | 1.32   | 7.16 |
| 35-44                                  | .000 | 5.77   | 2.37   | 14.05| .06    | 2.34   | 0.98   | 5.61 |
| 45-54                                  | .000 | 6.48   | 2.65   | 15.81| .02    | 2.77   | 1.16   | 6.61 |
| 55-64                                  | .001 | 4.84   | 1.90   | 12.34| .009   | 3.30   | 1.34   | 8.11 |
| >65                                    | .002 | 5.83   | 1.90   | 17.91| .06    | 3.21   | 0.96   | 10.76|
| Primary disease                        | .764 |        |        | .13  |        |        |        |      |
| AL, MDS, MPN (reference)               |      |        |        |      |        |        |        |      |
| CML                                    | .50  | 0.82   | 0.47   | 1.44 | .02    | 0.33   | 0.13   | 0.86 |
| Lymphoma, CLL, myeloma                 | .21  | 0.73   | 0.45   | 1.20 | .67    | 0.88   | 0.49   | 1.58 |
| Solid tumors                           | .55  | 0.79   | 0.36   | 1.72 | .31    | 0.57   | 0.20   | 1.67 |
| Nonmalignant disorders                 | .72  | 0.84   | 0.33   | 2.15 | .49    | 1.32   | 0.60   | 2.91 |
| Risk status at HSCT                    |      |        |        |      |        |        |        |      |
| Standard risk (reference)              |      |        |        |      |        |        |        |      |
| High risk                              | .77  | 1.05   | 0.74   | 1.51 | .63    | 0.90   | 0.58   | 1.39 |
| Calendar year of HSCT                  | .35  |        |        | .29  |        |        |        |      |
| 1980-1989 (reference)                  |      |        |        |      |        |        |        |      |
| 1990-1994                              | .04  | 0.48   | 0.24   | 0.97 | .11    | 0.54   | 0.25   | 1.15 |
| 1995-1999                              | .15  | 0.65   | 0.36   | 1.17 | .19    | 0.64   | 0.32   | 1.26 |
| 2000-2004                              | .22  | 0.69   | 0.38   | 1.25 | .78    | 0.91   | 0.46   | 1.79 |
| 2005-2009                              | .29  | 0.71   | 0.37   | 1.34 | .36    | 0.70   | 0.32   | 1.51 |

Abbreviations: AL, acute leukemia; CI, confidence interval; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; HR, hazard ratio; inf, inferior; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; sup, superior.

### TABLE 3. Death Rates per 100,000 Person-Years, Expected Death Rates, Standardized Mortality Ratio, and Absolute Excess Ratio per 100,000 for Suicides and Accidents, Including All Patients After Hematopoietic Stem Cell Transplantation and Stratified by Sex

| Population    | Person-Years | Suicide Rates per 100,000 | Expected Suicide Ratesa | O/E | SMR (95% CI) | AER (for 100,000) |
|---------------|--------------|--------------------------|-------------------------|-----|--------------|-------------------|
| Deaths by suicide |              |                          |                         |     |              |                   |
| Overall       | 915,183      | 20.7                     | 9.2                     | 189/89 | 2.12 (1.83-2.45) | 10.91             |
| Male          | 510,700      | 27.4                     | 14.0                    | 140/71 | 1.96 (1.65-2.31) | 13.41             |
| Female        | 401,401      | 12.2                     | 4.4                     | 49/18  | 2.77 (2.05-3.67) | 7.81              |
| Deaths by accident |            |                          |                         |     |              |                   |
| Overall       | 915,183      | 13.7                     | 10.5                    | 125/102 | 1.23 (1.02-1.46) | 2.54              |
| Male          | 510,700      | 18.0                     | 16.3                    | 92/83  | 1.11 (0.89-1.36) | 0.98              |
| Female        | 401,401      | 8.2                      | 4.6                     | 33/18  | 1.83 (1.26-2.57) | 1.64              |

aExpected death rates from Eurostat.

Abbreviations: AER, absolute excess ratio for 100,000; O/E, observed number versus expected number of deaths; SMR, standardized mortality ratio.
Furthermore, one-third of outpatients with cancer have suicidal ideation. A large cohort study of Swedish patients who recently received a cancer diagnosis found these individuals were at increased risk of suicide death, compared with cancer-free persons. Following solid-organ transplantation, depression appears to be one of the most common psychiatric disorders. Posttransplant depressive disorders occur between 5% and 25% in patients, and suicide rate after renal transplantation may be higher than expected in the general population.

There is a paucity of data on suicide death after HSCT. In our study, the difference in risk elevation for suicide observed between allogeneic and autologous HSCT, ie, chronic GVHD after allogeneic and relapse after autologous transplantation, is conceivable. Serious GVHD leads to disability, chronic illness, and reduced patient-reported quality of life, and may therefore explain the higher risk of suicide in patients treated with allogeneic HSCT. In contrast, relapse of the primary disease is the main concern after autologous HSCT. Cancer patients with poor survival expectation and poor prognosis facing the possibility of palliative care are at highest risk of suicide. In a large study including 121,533 cancer patients, cancer recurrence shortly after treatment completion was postulated to be a trigger for suicide. In our study, the excess of suicide after relapse can be explained by the perception of a desperate issue after having failed a “last-chance” treatment. Cancer patients treated with HSCT probably have an additional risk for suicide death. Indeed, in cancer patients, this risk is highest immediately after diagnosis of the cancer. At the time of transplantation, most patients have already been confronted with the diagnosis of malignancy and have received intensive chemotherapy. Therefore, they have overcome the main period of risk for suicide death due to the cancer itself. Nevertheless, to determine if HSCT patients are at additional risk for suicide, a study comparing patients with a similar malignant disease treated with and without HSCT should be performed.

In this study, relapse was also related with higher risk of accidental death after autologous HSCT. Several reasons could explain the excess of deaths by accidents after HSCT. Accidents are associated with psychological impairments, anxiety, and life events. No risk factors for accidents have been found with allogeneic HSCT. Accidents can be attributed to inattention, poor sight or hearing, slow reactions, and other medical issues. Moreover, the close relationship between relapse and accidental death after autologous transplantation points to the possibility that some of the accidents may be intentional, and therefore represent a hidden suicide. Therefore, physical and psychological distress appearing after HSCT may be involved in the excess of accidents. In long-term survivors after allogeneic HSCT, late effects such as cataract, cardiovascular complications, neurological complications, as well as decreased cognitive functioning may occur, and be incriminated for the increased risk of accidental death.

The major strength of our study is the large-scale population-based cohort with essentially complete ascertainment of transplants and fatal outcomes in Europe. The cohort was large enough to provide reliable data on death rates by suicide and accidents. The case-control analysis allows for an evaluation of transplant-related risk factors. To the best of our knowledge, this is the first study to evaluate external cause of death on a large-scale cohort.

There are limitations to this study, mainly due to the retrospective design and the absence of data on specific nonfatal late complications after HSCT that could have indirect repercussions on accidental death, such as...
cardiovascular complications, neurological problems, decreased cognitive functioning, and visual or hearing acuity. Second, a potential bias for the validity of our findings could be the diverse way how suicide and accidental deaths are ascertained in the different European countries. Third, although suicide and accidents are at higher risk in patients who undergo transplantation, it remains unclear what makes the difference from other patients with similar medical risk, such as those with chronic illness and severe pain, end-stage renal disease, human immunodeficiency virus positivity, congestive heart failure, or chronic obstructive lung disease. Finally, we cannot rule out the possibility that there is an underestimation of deaths due to suicide or accidents. The source of the causes of death came from the EBMT registry, which is based on center reporting and not on certificate of death. However, this restriction would not affect the validity of our findings. We suggest that our conclusions are generalizable to patients treated with HSCT.

This is the first study to observe an increased risk for death due to suicide and accidents after HSCT, and to identify patients at risk. Relapse after autologous HSCT was associated with more suicides and accidents, and chronic GVHD after allogeneic HSCT with an excess of suicides. The transplant community and the health care providers should be informed about the possibility that a person after HSCT may be suicidal or be exposed to an accident. However, there are still open questions that need to be addressed in further studies. It is conceivable that in addition to chronic GVHD or relapse, other relevant risk factors such as deterioration of quality of life, adverse social issues, or specific physical and mental limitations could be responsible for the increased suicide or accidental death rate in patients treated with HSCT. Such a type of data was not available in this large registry, but perhaps next-generation studies could assist in defining patients at risk. Furthermore, suicide and accidental death

### TABLE 4. Nested Case-Control Study for the Risk of Suicide and Accidents

| Characteristics | Cases (n = 187) | Controls (n = 560) | P  |
|-----------------|-----------------|-------------------|----|
|                  | Suicide Death   | Accidental Death  |     |
| All patients treated with HSCT |                  |                   |    |
| High risk at HSCT | 76/174 (44%)    | 233/520 (45%)     | .8 |
| Relapse          | 52/186 (28%)    | 81/554 (15%)      |    |
| Patients treated with allogeneic HSCT |              |                   |    |
| Family donor     | 49/71 (69%)     | 143/212 (67%)     | .81|
| Reduced intensity conditioning | 12/68 (18%)    | 36/201 (18%)      | .96|
| Relapse          | 10/71 (14%)     | 21/212 (10%)      | .32|
| Acute GVHD       | 28/69 (41%)     | 62/194 (32%)      | .2 |
| Chronic GVHDb    | 29/45 (64%)     | 62/168 (37%)      | .001|
| TBI in MAC       | 34/55 (62%)     | 106/162 (65%)     | .63|
| Patients treated with autologous HSCT |           |                   |    |
| High risk at HSCT| 65/110 (59%)    | 179/320 (58%)     | .57|
| Relapse          | 42/115 (37%)    | 60/342 (18%)      | .0001|
| TBI              | 17/104 (16%)    | 43/314 (14%)      | .5 |

a Case-control matching criteria included type of HSCT, age at HSCT by decade, sex of the patients, year of transplantation, and length of follow-up.

b Including only patients surviving at least 100 days after HSCT.

Abbreviations: GVHD, graft-versus-host disease; HSCT, hematopoietic stem cell transplantation; MAC, myeloablative conditioning; TBI, total body irradiation.

### TABLE 5. Nested Case-Control Study: Conditional Logistic Regression Analyses for the Risk of Suicide and Accidents

| Parameter | Suicide Death | Accidental Death |
|-----------|---------------|------------------|
|           | Odds Ratio    | 95% CI | P  | Odds Ratio | 95% CI | P  |
| Allogeneic HSCT |                  |        |    |            |        |    |
| No GVHD |               | 1     | .02|              |        |    |
| With GVHD| 2.91           | 1.16-7.23 |     | 1.16-4.81 | .32 |
| Risk group at HSCT | Standard risk | 1     | .08|              |        |    |
| High risk | 0.36           | 0.11-1.12 |     | 1.16-4.81 | .32 |
| Relapse |               |        |    |              |        |    |
| None | 1              | .0001 | 1  | .02|              |        |    |
| Yes | 4.48           | 2.3-8.76 | 2.36| 1.16-4.81 | .32 |
| Risk group at HSCT | Standard risk | 1     | .81 |              |        |    |
| High risk | 0.94           | 0.57-1.56 | 0.73| 0.39-1.36 | .48 |
| TBI for conditioning | None | 1     | .45 |              |        |    |
| Yes | 1.32           | 0.64-2.71 | 0.66| 0.20-2.11 | .48 |

Abbreviations: CI, confidence interval; GVHD, graft-versus-host disease; HSCT, hematopoietic stem cell transplantation; TBI, total body irradiation.
cannot be ignored in data analysis on transplant outcome. These deaths have to be classified as transplant-related or external cause of death.

FUNDING SOURCES
No specific funding was disclosed.

CONFLICT OF INTEREST DISCLOSURE
The authors made no disclosure.

REFERENCES
1. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354:1813-1826.
2. Gravwold A, Baldomero H, Aljurf M, et al; Worldwide Network of Blood and Marrow Transplantation. Hematopoietic stem cell transplantation: a global perspective. JAMA. 2010;303:1617-1624.
3. Ljungman P, Bregni M, Brune M, et al; European Group for Blood and Marrow Transplantation. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant. 2010;45:219-254.
4. Gooley TA, Chien JW, Pegram SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363:2091-2101.
5. Bhatia S, Robison LL, Francisco L, et al. Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood. 2005;105:4215-4222.
6. Bhatia S, Francisco L, Carter A, et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood. 2007;110:3784-3792.
7. Wingard JR, Majhail NS, Brazauskas R, et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2011;29:2230-2239.
8. Socie G, Salooja N, Cohen A, et al. Nonmalignant late effects after allogeneic stem cell transplantation. Blood. 2005;101:3373-3385.
9. Tichelli A, Rovo A, Passweg J, et al. Late complications after hematopoietic stem cell transplantation. Expert Rev Hematol. 2009;2:583-601.
10. Robinson D, Renshaw C, Majhail NS, Brazauskas R, et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood. 2007;110:3784-3792.
11. Wingard JR, Majhail NS, Brazauskas R, et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2011;29:2230-2239.
12. Socie G, Salooja N, Cohen A, et al. Nonmalignant late effects after allogeneic stem cell transplantation. Blood. 2005;101:3373-3385.
13. Tichelli A, Rovo A, Passweg J, et al. Late complications after hematopoietic stem cell transplantation. Expert Rev Hematol. 2009;2:583-601.
14. Robinson D, Renshaw C, Okello C, Moller H, Davies EA. Suicide in cancer patients in South East England from 1996 to 2005: a population-based study. Br J Cancer. 2009;101:198-201.
15. Robson A, Scrutton F, Wilkinson L, MacLeod F. The risk of suicide in cancer patients: a review of the literature. Psychooncology. 2010;19:1250-1258.
16. Norkin M, Hsu JW, Wingard JR. Quality of life, social challenges, and psychosocial support for long-term survivors after allogeneic hematopoietic stem-cell transplantation. Semin Hematol. 2012;49:104-109.
17. Syrjala KL, Langer SL, Abrams JR, et al. Recovery and long-term function after hematopoietic stem cell transplantation for leukemia or lymphoma. JAMA. 2004;291:2353-2345.
18. Loberiza FR Jr, Rizzo JD, Bredeson CN, et al. Association of depressive syndrome and early deaths among patients after stem-cell transplantation for malignant diseases. J Clin Oncol. 2002;20:2118-2126.
19. Andrykowski MA, Brady MJ, Greiner CB, et al. ‘Returning to normal’ following bone marrow transplantation: outcomes, expectations and informed consent. Bone Marrow Transplant. 1995;15:573-581.
20. Andrykowski MA, Bishop MM, Hahn EA, et al. Long-term health-related quality of life, growth, and spiritual well-being after hematopoietic stem-cell transplantation. J Clin Oncol. 2005;23:599-608.
21. Wasserman D, Rihmer Z, Rujescu D, et al. The European Psychiatric Association (EPA) guidance on suicide treatment and prevention. Eur Psychiatry. 2012;27:129-141.
42. Somes J, Donatelli NS. Car versus tree: accident or suicide attempt? *J Emerg Nurs.* 2011;37:179-181.

43. Belkacemi Y, Labopin M, Vernant JP, et al. Cataracts after total body irradiation and bone marrow transplantation in patients with acute leukemia in complete remission: a study of the European Group for Blood and Marrow Transplantation. *Int J Radiat Oncol Biol Phys.* 1998;41:659-668.

44. Tichelli A, Gratwohl A, Egger T, et al. Cataract formation after bone marrow transplantation. *Ann Intern Med.* 1993;119:1175-1180.

45. Tichelli A, Passweg J, Wojcik D, et al. Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. *Haematologica.* 2008;93:1203-1210.

46. Schmidt K, Schulz AS, Debatin KM, Friedrich W, Classen CF. CNS complications in children receiving chemotherapy or hematopoietic stem cell transplantation: retrospective analysis and clinical study of survivors. *Pediatr Blood Cancer.* 2008;50:331-336.

47. Friedman MA, Fernandez M, Wefel JS, Myszka KA, Champlin RE, Meyers CA. Course of cognitive decline in hematopoietic stem cell transplantation: a within-subjects design. *Arch Clin Neuropsychol.* 2009;24:689-698.

48. Wu LM, Austin J, Hamilton JG, et al. Self-efficacy beliefs mediate the relationship between subjective cognitive functioning and physical and mental well-being after hematopoietic stem cell transplant. *Psychooncology.* 2012;21:1175-1184.

49. Rizzo JD, Curtis RE, Socie G, et al. Solid cancers after allogeneic hematopoietic cell transplantation. *Blood.* 2009;113:1175-1183.

50. Tichelli A, Bucher C, Rovo A, et al. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. *Blood.* 2007;110:3463-3471.

51. Rovo A, Daikeler T, Halter J, et al. Late altered organ function in very long-term survivors after allogeneic hematopoietic stem cell transplantation: a paired comparison with their HLA-identical sibling donor. *Haematologica.* 2011;96:150-155.

52. Capron DW, Gonzalez A, Parent J, Zvolensky MJ, Schmidt NB. Suicidality and anxiety sensitivity in adults with HIV. *AIDS Patient Care STDS.* 2012;26:298-303.

53. Juurlink DN, Herrmann N, Szalai JP, Kopp A, Redelmeier DA. Medical illness and the risk of suicide in the elderly. *Arch Intern Med.* 2004;164:1179-1184.